Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D

 approved Novo Nordisk’s insulin icodec-abae under the name Awiqli for patients with 

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, highlight the FDA approval of once-weekly insulin icodec, emphasizing its significance as a major advancement in insulin therapy. They begin by addressing practical considerations, including its high concentration (U-700) and the implications for dosing, noting that weekly administration necessitates substantially higher unit doses compared with daily basal insulin.

The discussion focuses on dosing strategy, particularly the need to scale weekly doses approximately sevenfold relative to daily regimens, as well as the rationale for an initial loading dose of 1.5 times the calculated weekly requirement to more rapidly achieve steady state. Isaacs underscores the pharmacokinetic basis for this approach, given the drug’s long half-life and delayed time to steady state, while also noting the constraints of dosing in 10-unit increments.

Bellini and Isaacs explore the clinical implications of once-weekly insulin, with particular attention to adherence and treatment burden. Bellini emphasizes the potential benefit for insulin-naive patients and those struggling with daily injection adherence, framing weekly insulin as a means to significantly reduce injection frequency and improve consistency. Isaacs expands on this, arguing that reduced dosing frequency may mitigate missed doses and glycemic variability, especially in patients with irregular routines. Both highlight the flexibility afforded by the long half-life, allowing for minor deviations in dosing timing without substantial impact on glycemic control.

The conversation also addresses potential risks, including delayed titration and the possibility of over-basalization, particularly in patients with fluctuating nutritional intake or socioeconomic instability. They stress the importance of careful patient selection and monitoring, given the longer interval required to adjust doses.

Reviewing clinical trial data from the ONWARDS phase 3 program, the hosts note that once-weekly insulin demonstrated modestly greater A1C reduction compared with daily basal insulin in treat-to-target trials, reinforcing the hypothesis that improved adherence may translate into better glycemic outcomes.

They further discuss implementation considerations across care settings, highlighting potential advantages for older adults, caregivers, and patients in long-term care, where reduced injection burden may improve safety, independence, and medication management. The episode also touches on current regulatory limitations, noting that while approval is presently limited to type 2 diabetes in the United States, ongoing studies may expand its indication to type 1 diabetes, with off-label use anticipated in select cases.

The hosts conclude by situating weekly insulin within the broader therapeutic landscape, emphasizing renewed innovation in insulin development alongside incretin-based therapies. They note that additional agents in development may soon expand options within this class, signaling a meaningful shift in the management of diabetes toward more patient-centered, lower-burden treatment paradigms.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Novo Nordisk. Awiqli approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. March 26, 2026. Accessed April 3, 2026. 

https://ml-eu.globenewswire.com/Resource/Download/cb9dda59-1286-4718-a7e5-4256e2397b0c

Kunzmann K. FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. 

. March 26, 2026. Accessed April 3, 2026. 

https://www.hcplive.com/view/fda-approves-awiqli-insulin-icodec-first-once-weekly-basal-insulin-for-type-2-diabetes

Podcasts

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Videos

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Mardi Gomberg-Maitland, MD, MSc, is the director of the pulmonary hypertension program, chief clinical research officer at the Office of Clinical Research SMHS, and a professor of medicine at George Washington University.

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc

Sotatercept has reduced pulmonary vascular resistance (PVR) in combined post- and pre-capillary pulmonary hypertension (CpcPH) 

heart failure with preserved ejection fraction (HFpEF)

, improving both pulmonary vascular and cardiac end points, according to data from the CADENCE trial.

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, by Mardi Gomberg-Maitland, MD, MSc, director of the pulmonary hypertension program, chief clinical research officer at the Office of Clinical Research SMHS, and professor of medicine at George Washington University.

“Here we have a drug for a disease that we’ve never had therapy for, one that has high morbidity and mortality, and now we have potential,” Gomberg-Maitland told 

 in an exclusive interview. “We’re seeing good effects – now it’s time that we move to the next phase, to phase 3.”

CADENCE is an ongoing phase 2, multicenter, double-blind, randomized trial investigating the efficacy, safety, and tolerability of sotatercept in patients with CpcPH-HFpEF. The trial consisted of a 24-week placebo-controlled treatment period and an active-drug extension period. Gomberg-Maitland and colleagues reported the placebo-controlled period, during which patients were randomly assigned in a 1:1:1 ratio to receive subcutaneous sotatercept at 0.3 mg/kg (before potential escalation to 0.7 mg/kg after 3 dosing visits) or placebo every 3 weeks.

Eligible patients were aged 18-85 years with symptomatic CpcPH-HFpEF diagnosed via an assessment of hemodynamics through right heart catheterization. Patients were excluded if they were diagnosed with another form of pulmonary hypertension, clinically significant lung disease, severe hepatic impairment, and/or cirrhosis, among other criteria.

CADENCE’s primary efficacy endpoint was the change from baseline in PVR at week 24. The key secondary efficacy endpoint was the change from baseline in 6-meter walk distance at week 24. Other secondary endpoints included time to clinical worsening, which was defined as the time from the first dose date to the first occurrence of all-cause death or non-elective hospitalization for cardiopulmonary indications related to pulmonary hypertension and/or heart failure, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, NYHA functional class, and hemodynamic or echocardiographic parameters.

A total of 164 patients were randomized, with 54 assigned to sotatercept 0.3 mg/kg, 55 assigned to 0.7 mg/kg escalated from 0.3, and 55 assigned to placebo. The median duration of follow-up during this period was 5.6 months (interquartile range [IQR], 5.5-5.7) in the 0.3 mg/kg group, 5.6 months (IQR, 5.5-5.8) in the 0.7 mg/kg group, and 5.6 months (IQR, 5.5-5.8) in the placebo group.

By week 24, sotatercept treatment resulted in substantially greater reductions in PVR versus placebo. The median change from baseline was -0.67 Wood units in the 0.3 mg/kg group, -0.33 Wood units in the 0.7 mg/kg group, and 0.26 Wood units in the placebo group. The Hodges-Lehmann shift estimate was -1.02 Wood units (95% CI, -1.81 to -0.23; 

 = .004) for the 0.3 mg/kg group and -0.75 Wood units (95% CI, -1.52 to 0.03; 

 = .024) for the 0.7 mg/kg group compared to placebo. These results were consistent across subgroups, including the degree of PVR elevation at baseline.

Mean pulmonary arterial pressure saw a mean reduction of -9.19 mmHg (95% CI, -13 to -5.38) and -9.22 (95% CI, -12.97 to -5.46) in the 0.3 mg/kg and 0.7 mg/kg groups, respectively. Changes in 6-minute walk distance were 20.3 meters (95% CI, 1.5 to 39.1) for the 0.3 mg/kg group and 5.8 meters (95% CI, -17.3 to 28.9) for the 0.7 mg/kg group.

Ultimately, Gomberg-Maitland and colleagues noted that these findings provide an effective proof of concept for improved pulmonary vascular and cardiac hemodynamics following activin signaling inhibition with sotatercept in patients with CpcPH-HFpEF.

“As for how it can impact therapy, we’re going to continue into our phase 3 trials to really look at these echo parameters over time and see if this is perhaps a way that we can follow patients,” Gomberg said. “Ultimately, you don’t want to be doing right heart casts on everybody to see how they’re doing. We need other assessments that are more functional.”

Editors’ Note: Gomberg-Maitland reports disclosures with Merck, Catalys Pacific, Gossamer, Janssen Pharmaceuticals, Medtronic, Novartis, and others.

Gomberg-Maitland M, Tedford R, Langleben D, et al. Efficacy and Safety of Sotatercept in Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: results from the Phase 2 Cadence Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, Louisiana. March 28-30, 2026.

Gomberg-Maitland M, Tedford RJ, Langleben D, et al. Sotatercept for combined post- and pre-capillary pulmonary hypertension associated with heart failure: Results from the phase 2, randomized, placebo-controlled Cadence Study. 

Gomberg-Maitland addresses sotatercept’s capacity to improve pulmonary vascular and cardiac endpoints in patients with CpcPH-HFpEF.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

New Therapeutic Options Raise More Questions for IgA Nephropathy Treatment, With Sayna Norouzi, MD

Evidence shows a continually and rapidly expanding therapeutic landscape for patients with IgA nephropathy (IgAN). Due to the heterogeneity of the disease, clinicians remain undecided about how to approach these options with the IgAN’s complex, individualized presentation.

“It's getting more and more complicated with having more options out there, and we still have ongoing clinical trials, and we recruit for these trials as well. We have to keep in mind that we don't have a cure for IgAN yet, and we're not done with this field,” Norouzi siad. “I think the next step for a lot of our colleagues who are not spending a lot of time with IgAN patients would be a referral to a glomerular disease clinic or center of excellence.”

At WCN, a plethora of data supporting positive progress in IgAN was presented. In a

, Norouzi highlighted the emergence of targeted agents, including targeted-release budesonide, endothelin receptor antagonists like sparsentan and atrasentan, complement inhibitors such as iptacopan, and newer APRIL-targeting therapies. Together, these agents provide clinicians with multiple avenues to reduce proteinuria and preserve kidney function.

“When I go back from every conference that I attend to my clinic, my patients are excited. Sometimes I share with them that I'm going to a conference, and they know when I come back, I'm going to have more data, and they might have more options for their disease. And it's not just about IgAN. We're getting more options for C3G, lupus nephritis,” she concluded. “It's an exciting time to be a nephrologist.”

Norouzi reports relevant disclosures with Calliditas, Travere, Apellis and others.

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 ushered in a new wave of groundbreaking research into 

, and more. With hundreds of experts presenting hundreds of new studies and analyses, every aspect of cardiology received its fair share of updates.

With such a deluge of information, updates, and trial results, the 

 editorial team has collected 5 of the most impactful Phase 2 and 3 trials that should be on every clinician’s radar. Catch up on the biggest news from ACC.26 below:


Tonlamarsen Lowers Angiotensinogen, Mixed Results for Blood Pressure, With Luke Laffin, MD


KARDINAL was a randomized, placebo-controlled phase 2 trial of tonlamarsen in patients with uncontrolled hypertension, aiming to evaluate its efficacy in reducing plasma angiotensinogen and blood pressure. Presented by Luke Laffin, MD, co-director of the Center for Blood Pressure Disorders at Cleveland Clinic, these data showed a substantially greater percentage reduction in angiotensinogen among patients receiving monthly doses, with a least-squares mean percent change of -67.2%. However, tonlamarsen displayed no meaningful difference in blood pressure reduction between monthly doses and a single dose followed by placebo.


SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS


The SCOUT-HCM phase 3 trial is still ongoing, but at ACC.26, Joseph Rossano, MD, MS, co-director of the Cardiac Center at the Children’s Hospital of Philadelphia, presented data on mavacamten’s efficacy in reducing left ventricular outflow in adolescents with 

obstructive hypertrophic cardiomyopathy (HCM)

 compared to placebo. The analysis included 44 patients; of these, the 23 assigned to receive mavacamten saw dramatic reductions in mean Valsalva left ventricular outflow tract gradient compared to placebo recipients.


Evolocumab Reduces CV Risk in Non-Atherosclerotic Patients With Diabetes, With Nicholas Marston, MD, MPH


This secondary analysis of the VESALIUS-CV trial, presented by Nicholas Marston, MD, MPH, a preventive cardiologist at Brigham and Women’s Hospital, highlighted oral PCSK9 inhibitor evolocumab’s capacity to lower 

 in high-risk patients without a history of major cardiovascular events and with diabetes. A composite endpoint including coronary heart disease death, myocardial infarction, or ischemic stroke – as well as a 4-part endpoint including ischemia-driven arterial revascularization – occurred far less among patients treated with evolocumab compared to those receiving placebo.


MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension


Presented by Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Fuster Heart Hospital, the MOMENTUM trial revealed that the prevalence of endogenous hypercortisolism may be significantly higher among patients with resistant hypertension than previously thought. Investigators identified the condition in more than 1 in 4 patients of the 1086 screened, evaluating each patient via a 1-mg overnight dexamethasone suppression test. Bhatt and colleagues hope the results will support increased screening for hypercortisolism moving forward.


CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs


Device-based left atrial appendage closure was noninferior to non-vitamin K antagonist oral anticoagulant therapy (NOAC) for preventing adverse events in patients with atrial fibrillation, according to data from the CHAMPION-AF trial. Presented by Saibal Kar, MD, program director of the cardiovascular disease fellowship at Los Robles Regional Medical Center in California, this trial enrolled 3000 patients with non-valvular atrial fibrillation, assigning them to either the Watchman Fix device or an approved NOAC. At 3 years, a composite endpoint of cardiovascular death, stroke, or systemic embolism occurred in 81 patients in the device group and 65 in the NOAC group, while non-procedure-related bleeding occurred in 10.9% of the device group and 19% of NOAC patients.

Catch up on the most impactful trial readouts to come out of ACC 2026.

Arrhythmia

Cardiomyopathy

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Dyslipidemia

ACC 2026: Phase 2/3 Trials to Know

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 as a disease state commanded a notable share of the late-breaking data presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, Colorado, with research spanning a broad and rapidly evolving therapeutic landscape, from established biologics accumulating long-term comparative and extension data to emerging oral medications designed to meaningfully shift how psoriasis is managed in the years to come.

Several themes ran through much of the psoriasis program, including the growing momentum behind oral targeted treatments and the continued push to validate sustained skin clearance well beyond the 16-week primary endpoints known to have historically defined the field. Nail psoriasis and generalized pustular psoriasis (GPP) also featured in the data released at the meeting, reflecting a broader effort to address the full clinical spectrum of psoriatic disease. The following 6 updates from AAD represent key trials clinicians managing psoriasis should know:

ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD

One set of trials from AAD was ONWARD1 and 2, highlighting new phase 3 data for envudeucitinib. This drug, a next-generation, highly selective oral TYK2 inhibitor, demonstrating robust skin clearance in moderate-to-severe plaque psoriasis, was discussed by Andrew Blauvelt, MD, MBA, owner of Blauvelt Consulting, LLC, and principal investigator on the ONWARD program. Both ONWARD1 and ONWARD2 together enrolled more than 1700 adult patients living with moderate-to-severe plaque psoriasis.

Sustained PASI Responses Observed Through Week 60 with Zasocitinib, With Melinda Gooderham, MD

The LATITUDE trial program, highlighted during the AAD late-breaking data sessions, suggests zasocitinib could help to reshape the oral treatment landscape for moderate-to-severe plaque psoriasis. The drug was shown to have a high level of skin clearance, a result typically seen with biologics. Melinda Gooderham, MD, medical director of the SKiN Centre for Dermatology in Ontario, Canada, spoke about these key findings from the pair of pivotal phase 3 studies evaluating zasocitinib against both placebo and an active comparator, apremilast.

Risankizumab Outperforms Deucravacitinib on Psoriasis Clearance Across Patient Subgroups in Phase 4 Head-to-Head Trial

Risankizumab was another drug with new data presented during AAD, with findings demonstrating significantly greater skin clearance than deucravacitinib at the 16-week mark across an array of patient subgroups among adults with biologic-naïve moderate plaque psoriasis. These new data resulted from a subgroup analysis of the phase 4 IMMpactful trial, with the findings highlighting subgroup populations defined by race, sex, age, smoking status, baseline disease severity, body mass index (BMI), and presence of psoriatic arthritis (PsA).

ICONIC-LEAD: 1 Year Icotrokinra Data Confirm Durable Psoriasis Clearance, PRO Improvements in Adults, Adolescents, With Jennifer Soung, MD

Icotrokinra was another drug spotlighted during AAD, with 1-year data from the phase 3 ICONIC-LEAD trial confirming icotrokinra delivered durable skin clearance and meaningful patient-reported improvements among adults and adolescents with moderate-to-severe plaque psoriasis. ICONIC-LEAD investigators also identified no new safety signals through the 52-week mark. This medication became the first and only targeted oral peptide blocking the interleukin (IL)-23 receptor after being approved by the United States Food and Drug Administration (FDA) on March 18, 2026, for psoriasis.

Tildrakizumab Sustains Nail Psoriasis Efficacy Through 52 Weeks in Phase 3b Extension Data

New 52-week results also released during AAD showcased a phase 3b trial of tildrakizumab treatment of moderate-to-severe nail psoriasis, with these data demonstrating continued improvement in the level of nail clearance and sustained response seen among early responders, extending results first reported at last year’s AAD. Thia analysis is the first dedicated phase 3b trial of an IL-23 inhibitor in nail psoriasis.

EFFISAYIL ON: New Long-Term Data Released on Spesolimab Injection for GPP

Results from an ongoing open-label extension analysis were released by LEO Pharma at AAD regarding spesolimab-sbzo in adults with GPP. The EFFISAYIL ON analysis is an open-label extension trial lasting 5 years, designed to examine the long-term efficacy, safety, and tolerability of subcutaneous (SC) spesolimab in those who had previously partaken in either the EFFISAYIL 1 or EFFISAYIL 2 pivotal trials. These findings provide encouraging data suggesting this biologic agent can meaningfully diminish patients’ GPP flare burden over several years of treatment.

Articles

Late-breaking AAD 2026 psoriasis data emphasized sustained efficacy beyond traditional week-16 endpoints and accelerating innovation in oral targeted therapies. Phase 3 programs for next-generation TYK2 inhibition (envudeucitinib; zasocitinib) reported high PASI responses, with durability extending to week 60 for zasocitinib. A phase 4 head-to-head analysis showed risankizumab achieving superior week-16 clearance versus deucravacitinib across multiple prespecified subgroups. Longer-term datasets addressed broader phenotypes, including durable 52-week outcomes with icotrokinra and tildrakizumab in nail disease, and multi-year flare reduction with subcutaneous spesolimab for GPP.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

AAD 2026: 6 Psoriasis Trials to Know

Use of symptom and quality-of-life tools alongside biomarkers in PIONEER, principles of dose titration from 25 mg to 50 mg, and practical recommendations for longitudinal safety monitoring.

Video Series

Measuring Response in ISM: PRO Tools, Biomarkers, and Dose Optimization With Avapritinib

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Alopecia

AAD 2026: 7 Late-Breaking Data Updates to Know in Dermatology

Professor Stephen Nicholls is a world-renowned cardiologist, and leads the Victorian Heart Hospital (VHH) at Monash University.

Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.

Atherosclerotic Cardiovascular Disease

Obicetrapib is Safe and Well-Tolerated in HeFH and ASCVD, With Stephen Nicholls, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Data presented at the World Congress of Nephrology highlight faster and higher rates of microscopic hematuria negativity with sibeprenlimab treatment.

New VISIONARY Analyses Reinforce Benefits of APRIL Inhibition With Sibeprenlimab in IgAN

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Song speaks about JAK inhibitors and their safety in dermatology care settings, contextualizing previous data on adverse events.

Key Takeaways on JAK Inhibitors and Black Box Warnings, With Eingun James Song, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Seasonal Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

6 Allergy Headlines You Missed in March 2026

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

ASH publishes 33 clinical recommendations and 4 good practice statements for the diagnosis and treatment of severe and very severe acquired aplastic anemia. 

Hematology

ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia

Nicholls discusses the investigational oral CETP inhibitor’s effects on kidney health for patients at high risk of cardiovascular disease due to elevated HDL-C.

Chronic Kidney Disease

BROADWAY: Obicetrapib Preserves Kidney Function, Prevents CKD, With Stephen Nicholls, MD 

Marcello Tonelli, MD, is a nephrologist and professor of medicine at the University of Calgary, founding director of the World Health Organization Collaborating Centre on Prevention and Control of Chronic Kidney Disease, and president of the International Society of Nephrology.

The WHO resolution on kidney health elevates kidney disease as a global health priority, emphasizing early detection, treatment, and system-wide action.

Elevating Kidney Disease in Global Health Policy, With Marcello Tonelli, MD

Rajiv Agarwal, MD, MS, is a Professor Emeritus of Medicine at Indiana University School of Medicine and VA Medical Centre in Indianaoplis.

Further CONFIDENCE analyses support safe combination therapy in CKD, with improved responses in key patient subgroups.

Latest News

Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc

New Therapeutic Options Raise More Questions for IgA Nephropathy Treatment, With Sayna Norouzi, MD

ACC 2026: Phase 2/3 Trials to Know

AAD 2026: 6 Psoriasis Trials to Know